Abstract
We report the emergence of chronic myelogenous leukemia (CML) in a patient with JAK2V617F-positive polycythemia vera after 15 years of phlebotomy. The polycythemia vera clinical and molecular findings were suppressed at the time of CML diagnosis, only to re-emerge after the leukemia was successfully treated with imatinib. We explored the potential association between myeloproliferative disorders and CML in the context of the current literature and found a higher-than-expected coincidence based on known epidemiologic data for each specific condition. We hypothesize that myeloproliferative disorder (JAK2V617F or molecular events that cause JAK2V617F) is a risk factor for CML (BCR-ABL translocation). Because of therapeutic implications, clinicians should be aware that the conditions co-occur more frequently than once thought.
Original language | English (US) |
---|---|
Pages (from-to) | E25-E29 |
Journal | Clinical Lymphoma and Myeloma |
Volume | 9 |
Issue number | 5 |
DOIs | |
State | Published - Oct 1 2009 |
Keywords
- Erythrocytosis
- Myelofibrosis
- Phlebotomy
- Polycythemia vera
- Sleep apnea
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research